Altering sunitinib dosing schedule improves tolerability

Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, say Japanese researchers.02/23/2014
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news